Cornerstone Capital Inc. Purchases New Position in Gilead Sciences, Inc. $GILD

Key Points

• Cornerstone Capital purchased a new Gilead stake of 36,158 shares valued at approximately $4.57 million. Institutional investors and hedge funds now own 83.67% of the company.
• Gilead reported stronger-than-expected quarterly revenue of $7.80 billion, up 10.6% year over year, while its HIV franchise continued to drive growth. The company also declared a quarterly dividend of $0.82 per share, representing a 2.4% annualized yield.
• Analyst sentiment remains positive overall, with a consensus “Moderate Buy” rating and an average price target of $158.04, though some analysts have lowered their targets. Insiders sold 51,000 shares worth approximately $6.57 million over the past 90 days under pre-arranged trading plans.

Cornerstone Capital Inc. purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 36,158 shares of the biopharmaceutical company's stock, valued at approximately $4,568,000.

Several other hedge funds have also recently bought and sold shares of the stock. Paulson Wealth Management Inc. grew its position in shares of Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company's stock valued at $477,000 after purchasing an additional 67 shares during the last quarter. Essex Financial Services Inc. lifted its holdings in Gilead Sciences by 0.9% during the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company's stock worth $948,000 after purchasing an additional 71 shares during the last quarter. Davidson Trust Co. lifted its holdings in Gilead Sciences by 4.1% during the 1st quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company's stock worth $262,000 after purchasing an additional 74 shares during the last quarter. Alpha Cubed Investments LLC lifted its holdings in Gilead Sciences by 1.1% during the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company's stock worth $812,000 after purchasing an additional 75 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC boosted its stake in Gilead Sciences by 1.7% in the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company's stock valued at $546,000 after purchasing an additional 76 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $123.92, for a total value of $371,760.00. Following the completion of the transaction, the insider directly owned 124,234 shares in the company, valued at approximately $15,395,077.28. The trade was a 2.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares of the company's stock, valued at approximately $21,524,408.40. This trade represents a 1.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 51,000 shares of company stock worth $6,568,860. 0.30% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Appeals court ruling protects Gilead’s distribution channels. A U.S. appeals court upheld an injunction preventing alternative funding programs and related businesses from importing Gilead medications overseas. The decision could reduce the size of the alternative funding industry and help protect Gilead’s pricing, sales channels and patient-assistance economics. Court rules companies can't import Gilead medications from overseas in blow to AFP health programs
• Positive Sentiment: Q2 growth highlighted continued commercial momentum. Gilead’s HIV franchise led year-over-year sales growth, with Biktarvy and PrEP performing particularly well. Quarterly PrEP sales reportedly doubled to more than $1 billion, while Trodelvy, Livdelzi and progress in oncology and liver disease added to the growth outlook. 5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
• Positive Sentiment: AI collaboration strengthens the oncology pipeline. Gilead partnered with Nucleai to use AI-powered tissue analytics in its antibody-drug-conjugate programs. The technology is intended to accelerate biomarker discovery and improve precision-oncology development. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Merck partnership offers longer-term growth potential. Recent clinical and regulatory progress involving Gilead and Merck’s collaboration reinforces the possibility that the partnership could produce meaningful future growth in areas such as oncology and infectious disease. Could Merck and Gilead’s Partnership Create the Next Big Pharma Growth Engine
• Neutral Sentiment: Analysts and investors continue to debate whether Gilead remains attractively valued after its strong multiyear performance. High call-option activity signals bullish positioning but does not guarantee sustained gains.
• Negative Sentiment: An analyst reduced the FY2026 EPS forecast, potentially reflecting concerns about earnings normalization, expenses or pipeline investment. The revision may limit near-term upside despite Gilead’s solid revenue trends. FY2026 EPS Forecast for Gilead Sciences Reduced by Analyst

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $138.36 on Friday. The business has a fifty day moving average price of $130.11 and a two-hundred day moving average price of $136.45. The stock has a market capitalization of $171.56 billion, a PE ratio of -51.82 and a beta of 0.32. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter in the previous year, the firm earned $2.01 earnings per share. Gilead Sciences's revenue for the quarter was up 10.6% compared to the same quarter last year. As a group, equities analysts predict that Gilead Sciences, Inc. will post -0.53 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is currently -122.85%.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of research reports. HSBC raised Gilead Sciences from a "hold" rating to a "buy" rating and upped their price objective for the company from $133.00 to $155.00 in a report on Monday, July 6th. Leerink Partners cut shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. Weiss Ratings downgraded shares of Gilead Sciences from a "buy (b-)" rating to a "hold (c-)" rating in a research note on Tuesday. Wall Street Zen raised shares of Gilead Sciences from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, Rothschild & Co Redburn dropped their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Twenty-four investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $158.04.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source